1a68a242-045b-4566-afd7-192df87b02d3
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 90
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.500
- OXIDATIVE_PHOSPHORYLATION+0.500
- INTERFERON_ALPHA_RESPONSE+0.480
- FATTY_ACID_METABOLISM+0.470
- DNA_REPAIR+0.420
- PEROXISOME+0.410
- ADIPOGENESIS+0.400
- E2F_TARGETS+0.380
- INTERFERON_GAMMA_RESPONSE+0.380
- XENOBIOTIC_METABOLISM+0.380
Top 10 suppressed
- HEDGEHOG_SIGNALING-0.350
- UV_RESPONSE_DN-0.290
- APICAL_SURFACE-0.260
- WNT_BETA_CATENIN_SIGNALING-0.230
- KRAS_SIGNALING_DN-0.200
- MITOTIC_SPINDLE-0.190
- TGF_BETA_SIGNALING-0.190
- TNFA_SIGNALING_VIA_NFKB-0.180
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.140
- MYOGENESIS-0.120
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 94a92a4a-6c40-40c4-913d-0cdba8cb5892 | — | — | 0.886 |
| 2 | 77984740-019e-482f-822a-25a74ec2cc32 | — | — | 0.879 |
| 3 | 46E565A7-5022-4648-9035-B60FC7CFD6E7 | — | — | 0.851 |
| 4 | 2ad90ba0-8038-4bad-afa3-d176f63b42f0 | — | — | 0.851 |
| 5 | c7aea5a2-5772-4475-8ca6-326193eeb69e | — | — | 0.851 |
| 6 | 992ce1bc-46a2-4f57-ac7a-c6368c69c67c | — | — | 0.850 |
| 7 | a8e85cdd-3770-40a0-837e-6962ec12fcf0 | — | — | 0.849 |
| 8 | f6d998cd-20fa-4add-8fa7-6b89ff16f8bd | — | — | 0.841 |
| 9 | TCGA-BA-5152-01A-02R-1873-07 | — | — | 0.840 |
| 10 | 93708EED-CBE1-4B2E-A571-34316ACFE748 | — | — | 0.835 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 34 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.500 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.500 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.480 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.470 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.420 | Idelalisib | — uncovered |
| PEROXISOME | 0.410 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.400 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.380 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.380 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.380 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.370 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.360 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.340 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.320 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.300 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.280 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.240 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.220 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.220 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.210 | Idelalisib | — uncovered |